Protein-tyrosine phosphatase 1B (PTP-1B) mRNA (PTP-1B mRNA)

Protein-tyrosine phosphatase 1B (PTP-1B) mRNA is the messenger RNA transcript of the PTPN1 gene, which encodes a non-receptor tyrosine phosphatase that serves as a primary negative regulator of the insulin and leptin signaling pathways (UniProt P18031). The encoded protein, PTP1B, acts by dephosphorylating the insulin receptor and insulin receptor substrates (IRS-1), thereby terminating the insulin signal and contributing to insulin resistance in states of overabundance (PubMed 15644471). Targeting the PTP-1B mRNA specifically allows for the use of antisense oligonucleotides (ASOs) to reduce the cellular levels of the PTP1B protein through RNase H-mediated degradation of the transcript (PubMed 11854144). This therapeutic strategy aims to enhance insulin sensitivity and improve glycemic control in patients with type 2 diabetes and obesity (PubMed 17439551). Clinical candidates such as IONIS-PTP1B Rx (ISIS 113715) have been investigated in clinical trials to evaluate their efficacy in lowering blood glucose and HbA1c levels (NCT00330369). By reducing the expression of the PTP1B protein at the translational level, these therapies offer a potent alternative to small-molecule inhibitors, which have historically faced challenges regarding selectivity and bioavailability. This approach leverages the specificity of Watson-Crick base pairing to ensure that only the intended PTPN1 transcript is targeted, minimizing off-target effects compared to traditional enzyme inhibitors. Successful downregulation of PTP1B has been shown to improve metabolic profiles in various animal models and human clinical studies, highlighting its potential as a cornerstone for metabolic disease therapy.

Other names

PTPN1 mRNAProtein-tyrosine phosphatase non-receptor type 1 mRNAPTP1B transcript

Antisense oligonucleotide-mediated degradation of mRNA via RNase H, resulting in reduced translation of the PTP1B protein.